 |
 |

Noninvasive Ventilation in Myasthenic Crisis
Janaka Seneviratne, MBBS;
Jay Mandrekar, PhD;
Eelco F. M. Wijdicks, MD;
Alejandro A. Rabinstein, MD
Arch Neurol. 2008;65(1):54-58.
Background Myasthenic crisis (MC) is often associated with prolonged intubation and with respiratory complications.
Objectives To assess predictors of ventilation duration and to compare the effectiveness of endotracheal intubation and mechanical ventilation (ET-MV) with bilevel positive airway pressure (BiPAP) noninvasive ventilation in MC.
Design Retrospective cohort study.
Setting Academic research.
Patients We reviewed consecutive episodes of MC treated at the Mayo Clinic, Rochester, Minnesota.
Main Outcome Measures Collected information included patients' demographic data, immunotherapy, medical complications, mechanical ventilation duration, and hospital lengths of stay, as well as baseline and preventilation measurements of forced vital capacity, maximal inspiratory and expiratory pressures, and arterial blood gases.
Results We identified 60 episodes of MC in 52 patients. BiPAP was the initial method of ventilatory support in 24 episodes and ET-MV was performed in 36 episodes. There were no differences in patient demographics or in baseline respiratory variables and arterial gases between the groups of episodes initially treated using BiPAP vs ET-MV. In 14 episodes treated using BiPAP, intubation was avoided. The mean duration of BiPAP in these patients was 4.3 days. The only predictor of BiPAP failure (ie, requirement for intubation) was a PCO2 level exceeding 45 mm Hg on BiPAP initiation (P = .04). The mean ventilation duration was 10.4 days. Longer ventilation duration was associated with intubation (P = .02), atelectasis (P < .005), and lower maximal expiratory pressure on arrival (P = .02). The intensive care unit and hospital lengths of stay statistically significantly increased with ventilation duration (P < .001 for both). The only variable associated with decreased ventilation duration was initial BiPAP treatment (P < .007).
Conclusions BiPAP is effective for the treatment of acute respiratory failure in patients with myasthenia gravis. A BiPAP trial before the development of hypercapnia can prevent intubation and prolonged ventilation, reducing pulmonary complications and lengths of intensive care unit and hospital stay.
Author Affiliations: Departments of Neurology (Drs Seneviratne, Wijdicks, and Rabinstein) and Biostatistics (Dr Mandrekar), Mayo Clinic, Rochester, Minnesota.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals
Alshekhlee et al.
Neurology 2009;72:1548-1554.
ABSTRACT
| FULL TEXT
Predictors of Extubation Failure in Myasthenic Crisis
Seneviratne et al.
Arch Neurol 2008;65:929-933.
ABSTRACT
| FULL TEXT
|